计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 ,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Information
MK-8353 (SCH900353) MK-8353 (SCH900353) is an orally bioavailable, selective, and potent ERK inhibitor that inhibits activated ERK1 and ERK2 in vitro, with IC50 values of 23.0 nM and 8.8 nM, respectively (IMAP kinase assay), and nonactivated ERK2, with an IC50 of 0.5 nM (MEK1-ERK2-coupled assay).
Targets
ERK2 (Cell-free assay); ERK1 (Cell-free assay) 7 nM; 20 nM
In vitro
MK-8353 is a potent and selective inhibitor of both active and inactive ERK1 and ERK2 kinases (IC50=20 and 7 nM, respectively). MK-8353 is not a potent inhibitor of human CYPs 1A2, 2C9, 2C19 or 2D6 but inhibits CYP 3A4 (pre-incubation) in vitro and shows inhibition of CYP 3A4 and 2C8 (IC50 = 1.7 & 3.5 μM), which can cause drug-drug interactions when co administered with drugs that are primarily metabolized by CYP 2C8 or 3A4. MK-8353 is a weak inhibitor of hERG current, producing 16% inhibition at 0.6 μM. The IC50 values for inhibiting cell prolifertion are 371, 51, and 23 nM in A2058, HT-29, and Colo-205 cells respectively. In addition to inhibiting the kinase activity of ERK, MK-8353 prevents the phosphorylation of ERK by MEK. MK-8353 demonstrates kinase selectivity over a 227-human kinase panel; no additional kinase in the panel is inhibited by more than 35% at the 0.1 μM concentration, and only 3 kinases (CLK2, FLT4, and Aurora B) are inhibited >50% at the 1.0 μM concentration.
In vivo
The in vivo pharmacokinetics and metabolism of MK-8353 are evaluated in male CD1 mice, Sprague Dawley (SD) rats, guinea pigs, beagle dogs, and cynomologus monkeys. With the exception of monkeys, MK-8353 shows moderate clearance after IV administration in all species, with a half-life range of 1.3-2.8 hr and a mean residence time range of 1.5-4.0 hr. Acceptable oral bioavailability is seen in mice, rats and dogs (23-80%) but low oral bioavailability in monkeys (2%). The permeability observed in Caco-2 cells was high (135 nm/sec), suggesting that intestinal absorption and permeability in humans should also be high. The steady-state volume of distribution in mice, dogs and monkeys are in the range of 0.9-3.3 L/kg, while in rats it is 0.1 L/kg. MK-8353 displays anti-tumor efficacy in several BRAF-mutant models.
Cell Research(from reference)
Cell lines:A2058 cells
Concentrations:0, 3, 10, 30, 100, 300 nM
Incubation Time:24 hours
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机杂环化合物 |
| 类(Class) | 吡啶及其衍生物 |
| 亚类(Subclass) | 吡唑基吡啶 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 吡唑基吡啶 |
| 其他上位类(Alternative Parents) | 苯基-1,2,4-三唑 α氨基酸及其衍生物 吲哚类 N-芳基酰胺 吡咯烷酰胺 烷基芳基醚 苯及其取代衍生物 氢化吡啶 N-烷基吡咯烷 叔羧酸酰胺 杂芳族化合物 吡唑类 三烷基胺 仲羧酸酰胺 氮杂环化合物 亚磺酰基化合物 二烷基硫醚 碳氢化合物衍生物 羰基化合物 有机氧化物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 1,2,4-三唑 - 3-吡唑基吡啶 - 芳基醚 - α-氨基酸或其衍生物 - 氨基酸 - 氨基酸或其衍生物 - 芳香族杂多环化合物 - 氮杂环 - 吡唑 - 苯基化合物 - 苯并吡唑 - 羰基 - 羧酰胺基 - 羧酸衍生物 - 二烷基硫醚 - 乙醚 - 杂芳香族化合物 - 烃衍生物 - 氢吡啶 - 吲唑 - 单环苯基基团 - N-烷基吡咯烷 - N-芳基酰胺 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机氮化合物 - 有机氧化合物 - 有机硫化合物 - 苯基-1,2,4-三唑 - 苯基三唑 - 吡唑 - 吡咯烷 - 吡咯烷羧酸或其衍生物 - 吡咯烷-3-甲酰胺 - 醛基 - 硫酰基化合物 - 三元脂肪胺 - 三芳基胺 - 叔羧酸酰胺 - 硫醚 - 三唑 |
| 描述(Description) | 该化合物属于吡唑啉吡啶类有机化合物。这类化合物具有吡唑啉吡啶骨架,即吡唑通过键与吡啶相连(非共环)。 |
| 外部描述符(External Descriptors) | 暂无 |
| ALogP | 4.176 |
|---|---|
| hba_count | 7 |
| HBD Count | 2 |
| Rotatable Bond | 10 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | M420811 |